Brainstorm Cell Therapeutics Inc (BCLI) — Capital Reinvestment Ratio

Latest as of June 2018: 3.91x

Brainstorm Cell Therapeutics Inc (BCLI) has a Capital Reinvestment Ratio of 3.91x as of June 2018, meaning it reinvests 4% of its operating cash flow ($55.00K) in capital expenditures ($215.00K). See how leveraged is Brainstorm Cell Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

3.91x

Capex / Operating Cash Flow

Operating Cash Flow

$55.00K

USD

Capital Expenditures

$215.00K

USD

Data as of

Jun 2018

Most recent filing

Annual Capital Reinvestment Ratio for Brainstorm Cell Therapeutics Inc (None–None)

Year-by-year Capital Reinvestment Ratio for Brainstorm Cell Therapeutics Inc from None to None. For live market cap and broader valuation context, see Brainstorm Cell Therapeutics Inc market capitalisation.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow